CoChat

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Stewart, Ross A, Pilié, Patrick G, Yap, Timothy A · 2018 · Cancer Research

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Abstract

PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-18-2652

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 111 references

Research works printed but not linked: 1

  1. Ledermann, 2015, Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 16, e158

Cited by

See all 244

Metadata

Authors
Stewart, R. A., Pilié, P. G., & Yap, T. A.
Affiliations
  • Pfizer (United States) (US)
  • 2Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Stewart, Ross A
Venue
Cancer Research
Published
2018-12-13
Volume
78
Issue
24
Pages
6717-6725
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2902324525
Cited by
239
References
110
Citations by year
2026: 11 · 2025: 23 · 2024: 25 · 2023: 36 · 2022: 44 · 2021: 44 · 2020: 38 · 2019: 17
FWCI
2.66
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords
PARP inhibitors, immune checkpoint inhibitors, PD-1/PD-L1 blockade, combination therapy, DNA repair deficiency, PD-L1 upregulation, DNA damage, cancer immunotherapy
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Antibodies, Antineoplastic Combined Chemotherapy Protocols, DNA Damage, Humans, Immune System, Immunotherapy, Inflammation, Neoplasms, Cell Death, Disease Progression, Translational Research, Biomedical, B7-H1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of PARP and Immune-Checkpoint Inhibitor Combinations. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-2652
The paper
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018). Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-2652

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.